Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13858890 | 0.87 | MAPT (0.56) | CYP3A4ALDH1A1TDP1TSHRGFER | |
| SCHEMBL11139354 | 0.86 | CYP3A4 (0.42) | CYP3A4ALDH1A1TDP1TSHRKMT2A | |
| SCHEMBL11221908 | 0.82 | TAAR1 (0.52) | ALDH1A1TDP1TSHRLOXL2MAOB | |
| SCHEMBL8625033 | 0.79 | HRH3 (0.50) | LOXL2MAPTCA12CA1CA2 | |
| SCHEMBL18427888 | 0.78 | HRH3 (0.41) | CYP3A4TSHRMAOBCA12CA1 | |
| 4,4'-Methylenedianiline SCHEMBL31734180 | 0.77 | CYP3A4 (0.70) | CYP3A4ALDH1A1TDP1TSHRGFER | |
| SCHEMBL692408 | 0.75 | GFER (0.59) | CYP3A4ALDH1A1TDP1TSHRGFER | |
| SCHEMBL3736025 | 0.74 | TAAR1 (0.48) | MAOBMEN1KMT2A | |
| SCHEMBL7069164 | 0.74 | TSHR (0.43) | CYP3A4ALDH1A1TSHR | |
| SCHEMBL96029 | 0.74 | TAAR1 (0.48) | LOXL2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 655 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | claimed |
| US-20230116913-A2 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | INVIVOGEN (FR) | 2023-04-13 | — | — | US | claimed |
| US-20220339287-A9 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | INVIVOGEN (FR) | 2022-10-27 | — | — | US | claimed |
| US-20210353760-A1 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | INVIVOGEN (FR) | 2021-11-18 | — | — | US | claimed |
| US-20210170037-A1 | BRANCHED SUGAR ALCOHOL-BASED COMPOUNDS, AND COMPOSITIONS AND METHODS THEREOF | CELLMOSAIC INC (US) | 2021-06-10 | — | — | US | claimed |
| CN-112584871-A | Branched sugar alcohol-based compounds and compositions and methods thereof | 希默赛生物技术公司 | 2021-03-30 | — | — | CN | claimed |
| EP-3731874-A1 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | Invivogen (FR) | 2020-11-04 | — | — | EP | claimed |
| EP-3505188-A1 | PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | Invivogen (FR) | 2019-07-03 | — | — | EP | claimed |
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | claimed |
| EP-2210900-A2 | Analogues of GLP-1 | IPSEN PHARMA (FR) | 2010-07-28 | — | — | EP | claimed |
| EP-0961619-A4 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL MYERS SQUIBB CO (US) | 2001-09-26 | — | — | EP | claimed |
| EP-0961619-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-08 | — | — | EP | claimed |
| EP-0941120-A1 | BRANCHED PEPTIDE LINKERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-09-15 | — | — | EP | claimed |
| WO-1998019705-A1 | BRANCHED PEPTIDE LINKERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-14 | — | — | WO | claimed |
| WO-1998013059-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-02 | — | — | WO | claimed |
| US-4381300-A | Sulphur analogs of cephalosporins having a nucleophile substituted in the 7 position | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1983-04-26 | — | — | US | claimed |
| US-4265882-A | Sulphur analogs of penicillins having a nucleophile substituted in the 6 and 7 position, respectively | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1981-05-05 | — | — | US | claimed |
| US-4093625-A | 6-Sulfur analogs of penicillins and cephalosporins | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1978-06-06 | — | — | US | claimed |
| US-4009159-A | PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-02-22 | — | — | US | claimed |
| US-3972774-A | BY AN ESTERASE ENZYME FROM BACILLUS | ELI LILLY AND COMPANY (US) | 1976-08-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170037-A1 | BRANCHED SUGAR ALCOHOL-BASED COMPOUNDS, AND COMPOSITIONS AND METHODS THEREOF | SIGLEC7, CD44, SIGLEC9 | CYP3A4 2720/4885ALDH1A1 112/4885TDP1 4139/4885 |
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | ADCY3, ADCY8, ADCY7 | CYP3A4 4244/4885ALDH1A1 819/4885TDP1 1467/4885 |
| US-20210353760-A1 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | STING1, CGAS, TLR9 | CYP3A4 4790/4885ALDH1A1 4585/4885TDP1 1701/4885 |
| US-20220339287-A9 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | STING1, CGAS, TLR9 | CYP3A4 4790/4885ALDH1A1 4585/4885TDP1 1701/4885 |
| US-20230116913-A2 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | STING1, CGAS, TLR9 | CYP3A4 4790/4885ALDH1A1 4585/4885TDP1 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.